Skip to main content
. Author manuscript; available in PMC: 2021 Jul 12.
Published in final edited form as: Cancer Immunol Res. 2019 Nov 26;8(2):203–216. doi: 10.1158/2326-6066.CIR-19-0554

Figure 4. Metabolic activities of CD103+ cancer-specific T cells.

Figure 4

(A) The extracellular acidification rates (ECAR) of antigen-stimulated CD103+ or CD103− T cells across an 80-minute period. SSX-2 (left) and NY-ESO-1 (right)(N, number of repeats=3). Injection of glucose, oligomycin, and 2-DG into cells are indicated. The ECAR of (B) basal glycolytic capacity and (C) the maximal glycolytic capacity of antigen-stimulated CD103+ or CD103− T cells (N, number of repeats=3). (D) The oxygen consumption rates (OCR) of antigen-stimulated CD103+ or CD103− T cells across an 80-minute period. SSX-2 (left) and NY-ESO-1 (right)(N, number of repeats=3). Injection of oligomycin, FCCP, and rotenone/antimycin A into cells are indicated. The OCR at (E) basal respiration stage and (F) the spare respiratory capacity of antigen-stimulated CD103+ or CD103− T cells (N, number of repeats=3). Data represented as median±S.E.M. *p-value<0.05; **p-values<0.01; ***p-values<0.001; ns, not significant. P-values were calculated using either paired student t-test with Wilcoxon adjustments, one-way or two-way ANOVA with Tukey post hoc analysis.